Global X S&P Biotech ETF
CURE
- A$60.22
- 1.17
- 1.91%
Global X S&P Biotech ETF CURE Strategy
The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.
The investment objective & strategy is a summary of the investment's principal strategy as written in the prospectus. This information is pulled from the most recent product disclosure document.
ETFs News & Analysis
etfs
What Australian investors are buying and selling
The Australian ETF and managed fund landscape at the end of 2025.
etfs
Young & Invested: The currency trap catching ETF investors off guard
Why your fund’s currency exposure matters more than you think.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,297.20 | 103.50 | -1.10% |
| CAC 40 | 8,394.32 | 186.43 | -2.17% |
| DAX 40 | 24,638.00 | 646.26 | -2.56% |
| Dow JONES (US) | 48,904.78 | 73.14 | -0.15% |
| FTSE 100 | 10,780.11 | 130.44 | -1.20% |
| HKSE | 25,793.51 | 266.34 | -1.02% |
| NASDAQ | 22,748.86 | 80.64 | 0.36% |
| Nikkei 225 | 56,279.05 | 1,778.19 | -3.06% |
| NZX 50 Index | 13,620.21 | 36.44 | -0.27% |
| S&P 500 | 6,881.62 | 2.74 | 0.04% |
| S&P/ASX 200 | 9,077.30 | 90.80 | -0.99% |
| SSE Composite Index | 4,126.98 | 55.61 | -1.33% |